Neurogene Inc.
A clinical-stage biotech developing genetic medicines for rare neurological diseases.
NGNE | US
Overview
Corporate Details
- ISIN(s):
- US64135M1053 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 535 W 24TH STREET, 10011 NEW YORK
- Website:
- https://www.neurogene.com/
- Sector:
- Manufacturing
Description
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases. The company utilizes its proprietary EXACT gene therapy platform, which is designed to deliver therapeutic transgenes with controlled expression to improve safety and efficacy over conventional gene therapies. Its lead product candidate, NGN-401, is in clinical development for the treatment of Rett syndrome. The company is also advancing a gene therapy program for CLN5 Batten disease. Neurogene operates its own GMP manufacturing facility to support its clinical programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Neurogene Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neurogene Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neurogene Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
